drug discovery
They aim to bring down the period and costs for new drug development.
The multiyear agreement will focus on speeding clinical trials and drug development in oncology and nonalcoholic steatohepatitis.
Also: Rupa Health raised $20 million for its lab test platform, and CancerIQ scooped up $14 million in Series B funding.
Automata aims to scale capacities for life scientists.
The company said the latest round brings its total raise to $47 million.
Valo’s flagship product is its Opal Computational Platform, designed to create a new model for drug discovery.
The partnership will work on a drug discovery programme for the genetic muscle wasting disorder.
This Series C comes less than a year after the startup closed its $200 million Series B in 2020.
Also: Vocalis Health and Mayo Clinic seek new pulmonary hypertension biomarkers; Sensyne Health and Microsoft's strategic partnership focuses on clinical AI co-development.
insitro unveiled a $143 million Series B round on the same day that fellow machine learning company Exscientia highlighted its own $60 million Series C raise.